<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39394248</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Plasma bioactive adrenomedullin predicts mortality and need for dialysis in critical COVID-19.</ArticleTitle><Pagination><StartPage>23787</StartPage><MedlinePgn>23787</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23787</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-74380-x</ELocationID><Abstract><AbstractText>COVID-19 is a severe respiratory disease affecting millions worldwide, causing significant morbidity and mortality. Adrenomedullin (bio-ADM) is a vasoactive hormone regulating the endothelial barrier and has been associated with COVID-19 mortality and other adverse events. This prospective cohort pilot study included 119 consecutive patients with verified SARS-CoV-2 infection admitted to two intensive care units (ICUs) in Southern Sweden. Bio-ADM was retrospectively analysed from plasma on ICU admission, and days 2 and 7. Information on comorbidities, adverse events and mortality was collected. The primary outcome was 90-day mortality, and secondary outcomes were markers of disease severity. The association between bio-ADM and outcomes was analysed using survival analysis and logistic regression. Bio-ADM on admission, day 2, and day 7 only moderately predicted 90-day mortality in univariate and multivariate Cox regression. The relative change in bio-ADM between sample times predicted 90-day mortality better even when adjusting for the SAPS3 score, with an HR of 1.09 (95% CI 1.04-1.15) and a C-index of 0.82 (95% CI 0.72-0.92) for relative change between day 2 and day 7. Bio-ADM had a good prediction of the need for renal replacement therapy in multivariate Cox regression adjusting for creatinine, where day 2 bio-ADM had an HR of 3.18 (95% CI 1.21-8.36) and C-index of 0.91 (95% CI 0.87-0.96). Relative changes did not perform better, possibly due to a small sample size. Admission and day 2 bio-ADM was associated with early acute kidney injury (AKI). Bio-ADM on ICU admission, day 2 and day 7 predicted 90-day mortality and dialysis needs, highlighting bio-ADM's importance in COVID-19 pathophysiology. Bio-ADM could be used to triage patients with a risk of adverse outcomes and as a potential target for clinical interventions.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnsson</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden. patrik.johnsson@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive and Perioperative Care in Malmö, Skåne University Hospital, 20502, Malmö, Sweden. patrik.johnsson@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sievert</LastName><ForeName>Theodor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive and Perioperative Care in Malmö, Skåne University Hospital, 20502, Malmö, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didriksson</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive and Perioperative Care in Malmö, Skåne University Hospital, 20502, Malmö, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friberg</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive and Perioperative Care in Malmö, Skåne University Hospital, 20502, Malmö, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frigyesi</LastName><ForeName>Attila</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive and Perioperative Care in Lund, Skåne University Hospital, 22185, Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>148498-78-6</RegistryNumber><NameOfSubstance UI="D053607">Adrenomedullin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053607" MajorTopicYN="Y">Adrenomedullin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adrenomedullin</Keyword><Keyword MajorTopicYN="N">Adult respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">Dialysis</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword></KeywordList><CoiStatement>All authors declare that they have no competing, financial, or other interests in SphingoTec GmbH and have not been influenced by SphingoTec GmbH in writing this research paper. Bioactive ADM was analysed free of charge by SphingoTec GmbH, Neuendorfstraße 15A, 16761 Hennigsdorf, Germany.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39394248</ArticleId><ArticleId IdType="pmc">PMC11470140</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-74380-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-74380-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ranieri, V. M. et al. Acute respiratory distress syndrome: The Berlin definition. JAMA307, 2526–2533 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Didriksson, I. et al. Intensive care unit burden is associated with increased mortality in critically ill COVID-19 patients. Acta Anaesthesiol. Scand.67, 329–338 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878196</ArticleId><ArticleId IdType="pubmed">36537243</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. Clinical Spectrum of SARS-CoV-2 Infection (2023).</Citation></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell181, 271–280 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrario, C. M. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation111, 2605–2610 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet395, 1417–1418 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirican, A., Ildir, S., Uzar, T., Karaman, I. &amp; Ozkaya, S. 190 patients and literature review for a pathophysiological map to clinical categorisation. Int. J. Clin. Pract.75, e14843 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646438</ArticleId><ArticleId IdType="pubmed">34519155</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaumenhaft, R., Enjyoji, K. &amp; Schmaier, A. A. Vasculopathy in COVID-19. Blood140, 222–235 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8736280</ArticleId><ArticleId IdType="pubmed">34986238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippenstiel, S. et al. Adrenomedullin reduces endothelial hyperpermeability. Circ. Res.91, 618–625 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12364390</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura, K. et al. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. 1993. Biochem. Biophys. Res. Commun.425, 548–555 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22925672</ArticleId></ArticleIdList></Reference><Reference><Citation>Jougasaki, M. &amp; Burnett, J. C. Adrenomedullin: Potential in physiology and pathophysiology. Life Sci.66, 855–872 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10714887</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez, A., Miller, M. J., Unsworth, E. J., Siegfried, J. M. &amp; Cuttitta, F. Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology136, 4099–4105 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7649118</ArticleId></ArticleIdList></Reference><Reference><Citation>Voors, A. A. et al. Adrenomedullin in heart failure: Pathophysiology and therapeutic application. Eur. J. Heart Fail.21, 163–171 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607488</ArticleId><ArticleId IdType="pubmed">30592365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockcroft, J. R., Noon, J. P., Gardner-Medwin, J. &amp; Bennett, T. Haemodynamic effects of adrenomedullin in human resistance and capacitance vessels. Br. J. Clin. Pharmacol.44, 57–60 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2042810</ArticleId><ArticleId IdType="pubmed">9241097</ArticleId></ArticleIdList></Reference><Reference><Citation>García Ponce, A. et al. Loss of cortactin causes endothelial barrier dysfunction via disturbed adrenomedullin secretion and actomyosin contractility. Sci. Rep.6, 29003 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4928053</ArticleId><ArticleId IdType="pubmed">27357373</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber, J. et al. Sandwich immunoassay for bioactive plasma adrenomedullin. J. Appl. Lab. Med.2, 222–233. 10.1373/jalm.2017.023655 (2019). https://academic.oup.com/jalm/article-pdf/2/2/222/31433623/jalm0222.pdf.</Citation><ArticleIdList><ArticleId IdType="pubmed">32630976</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino, R. et al. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit. Care18, R34 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056312</ArticleId><ArticleId IdType="pubmed">24533868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebazaa, A. et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: The prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit. Care22, 354 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6305573</ArticleId><ArticleId IdType="pubmed">30583748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg, O. H. M. et al. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit. Care24, 636 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7641835</ArticleId><ArticleId IdType="pubmed">33148300</ArticleId></ArticleIdList></Reference><Reference><Citation>Geven, C., Bergmann, A., Kox, M. &amp; Pickkers, P. Vascular effects of adrenomedullin and the anti-adrenomedullin antibody Adrecizumab in Sepsis. Shock50, 132–140 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29324626</ArticleId></ArticleIdList></Reference><Reference><Citation>de Guadiana-Romualdo, L. et al. MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur. J. Clin. Investig.51, e13511 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995076</ArticleId><ArticleId IdType="pubmed">33569769</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregoriano, C. et al. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: An observational study. Clin. Chem. Lab. Med.59, 995–1004 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33554516</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, N. et al. Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting. J. Clin. Pathol.76, 400–406 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">34996755</ArticleId></ArticleIdList></Reference><Reference><Citation>Sozio, E. et al. Identification of COVID-19 patients at risk of hospital admission and mortality: A European multicentre retrospective analysis of mid-regional pro-adrenomedullin. Respir. Res.23, 221 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9420187</ArticleId><ArticleId IdType="pubmed">36031619</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lier, D. et al. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: A prospective international multicentre study. ERJ Open Res.9, 00342–02022 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9571166</ArticleId><ArticleId IdType="pubmed">36628268</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, T. P. et al. Prognostic value of bioactive adrenomedullin in critically Ill patients with COVID-19 in Germany: An observational cohort study. J. Clin. Med.10, 1667 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8069401</ArticleId><ArticleId IdType="pubmed">33924637</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakas, M. et al. Targeting endothelial dysfunction in eight extreme-critically Ill patients with COVID-19 using the anti-adrenomedullin antibody Adrecizumab (HAM8101). Biomolecules10, 1171 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7465983</ArticleId><ArticleId IdType="pubmed">32796765</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialek, B. et al. Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proADM) as a prognostic marker in COVID-19-hospitalized patients. Ann. Med.55, 379–387 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9828692</ArticleId><ArticleId IdType="pubmed">36607317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievert, T. et al. Neurofilament light chain on intensive care admission is an independent predictor of mortality in COVID-19: A prospective multicenter study. Intensive Care Med. Exp.11, 66 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10539241</ArticleId><ArticleId IdType="pubmed">37768470</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet370, 1453–1457 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson, M. E., Pompei, P., Ales, K. L. &amp; MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis.40, 373–383 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno, R. P. et al. SAPS 3–From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med.31, 1345–1355 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1315315</ArticleId><ArticleId IdType="pubmed">16132892</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent, J. L. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.. Intensive Care Med.22, 707–710 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellum, J. A., Lameire, N. &amp; Group, K. A. G. W. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit. Care17, 1–15 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057151</ArticleId><ArticleId IdType="pubmed">23394211</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli, G. et al. ESICM guidelines on acute respiratory distress syndrome: Definition, phenotyping and respiratory support strategies. Intensive Care Med.49, 727–759 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10354163</ArticleId><ArticleId IdType="pubmed">37326646</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Z. et al. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). J. Leukoc. Biol.103, 749–759 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6312640</ArticleId><ArticleId IdType="pubmed">29360169</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieceli Dalla Sega, F. et al. ime course of endothelial dysfunction markers and mortality in COVID-19 patients: A pilot study. Clin. Transl. Med.11, e283 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919132</ArticleId><ArticleId IdType="pubmed">33784001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozhuharov, N. et al. Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure. Clin. Res. Cardiol.111, 627–637 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9151518</ArticleId><ArticleId IdType="pubmed">34302189</ArticleId></ArticleIdList></Reference><Reference><Citation>Roedl, K. et al. MR-proAdrenomedullin as a predictor of renal replacement therapy in a cohort of critically ill patients with COVID-19. Biomarkers26, 417–424 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33754916</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadim, M. K. et al. COVID-19-associated acute kidney injury: Consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat. Rev. Nephrol.16, 747–764 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561246</ArticleId><ArticleId IdType="pubmed">33060844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>